Results of 1-year follow-up examinations after intravitreal bevacizumab administration for idiopathic choroidal neovascularization

Retina

Volumn 30, Issue 5, 2010, Pages 733-738

  Inoue, Maiko ^a   Kadonosono, Kazuaki ^a   Watanabe, Yoichiro ^a   Sato, Shimpei ^a   Kobayashi, Satoshi ^a   Yamane, Shin ^a   Ito, Rieko ^a   Arakawa, Akira ^b  

^a YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^b Department of Ophthalmology   (Japan)

Author keywords

Bevacizumab; Idiopathic choroidal neovascularization

Indexed keywords

BEVACIZUMAB; TRIAMCINOLONE ACETONIDE;

ADULT; ARTICLE; BEST CORRECTED VISUAL ACUITY; CENTRAL RETINA FOVEA THICKNESS; CLINICAL ARTICLE; DRUG SAFETY; EYE DISEASE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; IDIOPATHIC DISEASE; LONG TERM CARE; MALE; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; RETINA EDEMA; RETINA FOVEA; RETREATMENT; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; SYSTEMIC DISEASE; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INJECTIONS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETREATMENT; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 77952247104     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181c9699c     Document Type: Article

References (22)

1. Cohen SY, Laroche A, Leguen Y, Soubrane G, Coscas GJ. Etiology of choroidal neovascularization in young patients. Ophthalmology 1996;103:1241-1244.
2. Cleasby GW. Idiopathic focal subretinal neovascularization. Am J Ophthalmol 1976;81:590-599.
3. Flaxel CJ, Owens SL, Mulholland B, Schwartz SD, Gregor ZJ. The use of corticosteroids for choroidal neovascularisation in young patients. Eye (Lond) 1998;12:266-272.
4. Kumar A, Prakash G, Singh RP. Transpupillary thermotherapy for idiopathic subfoveal choroidal neovascularization. Acta Ophthalmol Scand 2004;82:205-208.
5. Thomas MA, Grand MG, Williams DF, Lee CM, Pesin SR, Lowe MA. Surgical management of subfoveal choroidal neovascularization. Ophthalmology 1992;99:952-968; discussion 975-976.
6. Berger AS, Kaplan HJ. Clinical experience with the surgical removal of subfoveal neovascular membranes. Short-term postoperative results. Ophthalmology 1992;99:969-675; discussion 975-976.
7. Fujii GY, Humayun MS, Pieramici DJ, Schachat AP, Au Eong KG, de Juan E Jr. Initial experience of inferior limited macular translocation for subfoveal choroidal neovascularization resulting from causes other than age-related macular degeneration. Am J Ophthalmol 2001;131:90-100.
8. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 1999;117:1329-1345.
9. Chan WM, Lam DS, Wong TH, et al. Photodynamic therapy with verteporfin for subfoveal idiopathic choroidal neovascularization: one-year results from a prospective case series. Ophthalmology 2003;110:2395-2402.
10. Postelmans L, Pasteels B, Coquelet P, El Ouardighi H, Verougstraete C, Schmidt-Erfurth U. Severe pigment epithelial alterations in the treatment area following photodynamic therapy for classic choroidal neovascularization in young females. Am J Ophthalmol 2004;138:803-808.
11. Sii F, Lee LR. Retinopathy associated with photodynamic therapy for treatment of idiopathic choroidal neovascularization. Clin Experiment Ophthalmol 2006;34:184-186.
12. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular agerelated macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:43-58.
13. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol 2007;143:977-983.
14. Gomi F, Nishida K, Oshima Y, et al. Intravitreal bevacizumab for idiopathic choroidal neovascularization after previous injection with posterior subtenon triamcinolone. Am J Ophthalmol 2007;143:507-510.
15. Mandal S, Garg S, Venkatesh P, Mithal C, Vohra R, Mehrotra A. Intravitreal bevacizumab for subfoveal idiopathic choroidal neovascularization. Arch Ophthalmol 2007;125:1487-1492. (Pubitemid 350106680)
16. Argon laser photocoagulation for idiopathic neovascularization. Results of a randomized clinical trial. Arch Ophthalmol 1983;101:1358-1361.
17. Campochiaro PA, Morgan KM, Conway BP, Stathos J. Spontaneous involution of subfoveal neovascularization. Am J Ophthalmol 1990;109:668-675.
18. Lindblom B, Andersson T. The prognosis of idiopathic choroidal neovascularization in persons younger than 50 years of age. Ophthalmology 1998;105:1816-1820.
19. Fujii GY, Pieramici DJ, Humayun MS, et al. Complications associated with limited macular translocation. Am J Ophthalmol 2000;130:751-762.
20. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-372. e5.
21. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to agerelated macular degeneration. Retina 2006;26:383-390. (Pubitemid 44197628)
22. Nguyen QD, Shah S, Tatlipinar S, Do DV, Anden EV, Campochiaro PA. Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. Br J Ophthalmol 2005;89:1368-1370.